Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C14H21NO4.ClH |
| Molecular Weight | 303.782 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COCCOCCNCC1COC2=C(O1)C=CC=C2
InChI
InChIKey=DGDJOYSDXRNADN-UHFFFAOYSA-N
InChI=1S/C14H21NO4.ClH/c1-16-8-9-17-7-6-15-10-12-11-18-13-4-2-3-5-14(13)19-12;/h2-5,12,15H,6-11H2,1H3;1H
| Molecular Formula | C14H21NO4 |
| Molecular Weight | 267.3208 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Ambenoxan is a muscle relaxant. Ambenoxan exerts its effects via an action on brain and/or spinal mechanisms. Ambenoxan has been shown to produce skeletal muscle flaccidity without loss of the righting reflex when administered orally or parenterally to rats, rabbits, dogs and monkeys. The drug is approximately twice as toxic orally as it is subcutaneously, which suggests that the compound is effectively absorbed by the oral route. Ambenoxan may be of value in the treatment of spastic disorders resulting from upper motor neurone damage in the brain or spinal cord, disseminated sclerosis, spastic diplegia and spastic hemiplegia.
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:50:25 GMT 2025
by
admin
on
Mon Mar 31 22:50:25 GMT 2025
|
| Record UNII |
DHR4YM0G6V
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
15377
Created by
admin on Mon Mar 31 22:50:25 GMT 2025 , Edited by admin on Mon Mar 31 22:50:25 GMT 2025
|
PRIMARY | |||
|
DHR4YM0G6V
Created by
admin on Mon Mar 31 22:50:25 GMT 2025 , Edited by admin on Mon Mar 31 22:50:25 GMT 2025
|
PRIMARY | |||
|
1617-99-8
Created by
admin on Mon Mar 31 22:50:25 GMT 2025 , Edited by admin on Mon Mar 31 22:50:25 GMT 2025
|
PRIMARY | |||
|
DTXSID70936589
Created by
admin on Mon Mar 31 22:50:25 GMT 2025 , Edited by admin on Mon Mar 31 22:50:25 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ENANTIOMER -> RACEMATE | |||
|
|
ENANTIOMER -> RACEMATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |